Source: http://www.smart-biggar.ca/contacts/SheldonHamilton
Timestamp: 2019-04-20 21:13:45+00:00

Document:
Sheldon Hamilton has been recognized as one of Canada’s leading patent litigation lawyers. For close to 20 years, Sheldon has acted as counsel for many of the world’s most innovative companies in relation to commercially significant products. Sheldon has particular experience in pharmaceutical litigation, appearing as both trial and appellate counsel, including in proceedings under the Patented Medicines (Notice of Compliance) Regulations. Sheldon has extensive trial experience focusing on issues of patent infringement and validity, and damage quantification.
Sheldon has been recognized by a range of leading Canadian and international publications, including IAM Patent Litigation 250 — The World's Leading Patent Litigators, IAM Life Sciences 250 – The World’s Leading Life Sciences Patent Litigators, Benchmark Canada, Chambers Global, and The Best Lawyers in Canada. Praised by clients and colleagues alike as a “pharma whizz”, Sheldon has been recognized as prevailing in many tricky courtroom scenarios (IAM Patents 1000, 2017).
AstraZeneca Canada Inc. et al v. Mylan Pharmaceuticals ULC et al, 2011 FC 1023 — Court granted Order of prohibition rejecting generic's arguments of inutility and obviousness.
sanofi-aventis Canada Inc v. Pharmascience Inc., 2008 FC 782 — Court granted Order of prohibition following earlier finding that the generic was estopped from litigating the validity of the patent.
sanofi-aventis Canada Inc. v. Pharmascience Inc., 2007 FC 1057 — Court applied issue estoppel to preclude generic from litigating a second allegation of invalidity where the generic had initially failed on an allegation of invalidity and another generic had subsequently succeeded.
sanofi-aventis Inc. v. Laboratoire Riva Inc., 2007 FC 532 — Court would have found allegation of invalidity regarding compound patent not justified but ruled that it was bound by decision in another case that the same allegation was justified.
Aventis Pharma Inc. v. Pharmascience Inc., 2005 FC 340 — Allegation of invalidity not justified for compound patent.
AB Hassle v. Apotex Inc., 2005 FC 234 — Court applied issue estoppel to preclude generic from relitigating allegation of non-infringement and litigating allegation of invalidity that could have been raised in an earlier proceeding.
Astrazeneca AB v. Apotex Inc. and AB Hassle v. Apotex Inc., 2004 FC 761, 2004 FC 762 — Court permitted filing of further evidence related to testing of samples produced by generic.
AB Hassle v. Apotex Inc., 2003 FCT 771 — Allegation of invalidity of salt patent not justified.
AB Hassle v. Apotex Inc., 2002 FCT 931 — Allegation of non-infringement of formulation patents not justified.
Hassle v. Canada (Minister of National Health and Welfare), T-366-98 — Allegation of non-infringement of formulation patent not justified.
AB Hassle v. Canada (Minister of National Health and Welfare), T-1712-95 — Allegation of non-infringement of compound patent not justified on basis of non-infringing process; generic process is obvious chemical equivalent of patented process. Court prohibits Minister from issuing notice of compliance.
sanofi-aventis Canada Inc. v. Apotex Inc.; sanofi-aventis Canada Inc. v. Novopharm Inc., 2009 FC 676 — Actions for infringement and validity of compound patent and reference for damages. Cases proceeded to trial on all issues, including remedy, in two years.
Merck & Co. Inc. v. Apotex Inc., 2006 FC 524 — Compound patent valid and infringed; generic enjoined from further sale pending patent expiry and damages awarded to patentee and licensee.
Apotex Inc. v. Syntex Pharmaceuticals International Ltd., T-2870-96 — Sustained release formulation patent.
AB Hassle v. Canada (Minister of National Health and Welfare) and AstraZeneca Canada Inc. v. Canada (Minister of Health), 2004 FC 377, 2004 FC 378 — Court granted motion allowing use of confidential information from one proceeding in a judicial review application.
Hoffmann-La Roche Ltd. v. Canada (Minister of National Health and Welfare), T-2309-98 — Court quashed notice of compliance issued to generic.
Apotex Inc. v. sanofi-aventis Inc., 2008 FCA 394 — Court of Appeal upheld Trial Judge’s decision not to recuse herself from trial on the basis of reasonable apprehension of bias arising from an earlier decision by the same Judge.
Pharmascience Inc. v. sanofi-aventis Canada Inc., 2008 FCA 213 — Court of Appeal confirmed the application of issue estoppel where generic had failed on one allegation of invalidity and attempted to litigate a second allegation of invalidity on the basis of another generic's intervening success. The Court refused to allow the generic to relitigate.
Apotex Inc. v. Merck & Co., 2006 FCA 323 — Court of Appeal affirmed findings of infringement and validity of compound patent.
Pharmascience Inc. v. sanofi-aventis Canada Inc., 2006 FCA 210 — Court of Appeal dismissed motion by generic to have appeal dismissed as abuse of process.
Apotex Inc. v. AstraZeneca Canada Inc. and Apotex Inc. v. AB Hassle, 2004 FCA 226, 2004 FCA 227 — Court dismissed appeal from variation of protective Order allowing use of evidence from one proceeding in another proceeding.
Apotex Inc. v. AB Hassle, 2004 FCA 255 — Court of Appeal upheld trial decision permitting further evidence related to testing of samples provided by the generic.
Apotex Inc. v. AB Hassle, 2003 FCA 87 — Court of Appeal declined to admit fresh evidence on appeal.
Rhoxalpharma Inc. v. AB Hassle, 2002 FCA 147 — Court of Appeal affirmed decision that allegation of non-infringement regarding formulation patent was not justified.
Laboratoires Servier v. Apotex Inc., 2008 FC 321 — Court quashed subpoenas issued at request of generic to patent attorneys involved in settlement of prior proceeding.
sanofi-aventis Canada Inc. v. Apotex Inc., 2008 FC 320 — Court dismissed in part motion by generic for relief from the implied undertaking not to use discovery documents from one proceeding for purposes of another proceeding.
Apotex Inc. v. Syntex Pharmaceuticals International Ltd., T-2870-96 — Court dismissed motion by generic for summary judgment related to sustained release formulation patent.

References: v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v.